Flagship-founded Tessera fuels up with $300M 'to go on a really big adventure' in gene editing
A few years ago, the gene editing approach at Tessera was just a “twinkle in our eye,” CEO and co-founder Geoff von Maltzahn said.
Nucleases — the crucial machinery underlying the gene editing field — do a pretty good job of cutting DNA, allowing scientists to switch off a specific gene. But von Maltzahn and Jacob Rubens, Tessera’s co-founder and chief innovation officer, saw the opportunity in being able to do more.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.